Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Accured Expenses (2018 - 2023)

Historic Change in Accured Expenses for Autolus Therapeutics (AUTL) over the last 6 years, with Q3 2023 value amounting to $31.4 million.

  • Autolus Therapeutics' Change in Accured Expenses rose 72275.23% to $31.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $31.4 million, marking a year-over-year increase of 72275.23%. This contributed to the annual value of $40.8 million for FY2022, which is 7237.93% up from last year.
  • Per Autolus Therapeutics' latest filing, its Change in Accured Expenses stood at $31.4 million for Q3 2023, which was up 72275.23% from $31.0 million recorded in Q2 2023.
  • In the past 5 years, Autolus Therapeutics' Change in Accured Expenses ranged from a high of $40.8 million in Q4 2022 and a low of -$370000.0 during Q1 2019
  • Moreover, its 5-year median value for Change in Accured Expenses was $24.5 million (2022), whereas its average is $22.5 million.
  • In the last 5 years, Autolus Therapeutics' Change in Accured Expenses skyrocketed by 693739.61% in 2021 and then plummeted by 8667.67% in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Change in Accured Expenses stood at $21.4 million in 2019, then increased by 29.83% to $27.8 million in 2020, then dropped by 14.81% to $23.7 million in 2021, then surged by 72.38% to $40.8 million in 2022, then fell by 23.06% to $31.4 million in 2023.
  • Its Change in Accured Expenses was $31.4 million in Q3 2023, compared to $31.0 million in Q2 2023 and $34.5 million in Q1 2023.